ADPT Earnings Date: Nov 4, 2026 (Estimated) — Adaptive Biotechnologies Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is ADPT's next earnings date?
Adaptive Biotechnologies Corporation (ADPT) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.09 on revenue of $71.6M.
How did ADPT do in its last earnings report?
In its most recent report on Jul 29, 2026 (Q2 2026), Adaptive Biotechnologies Corporation posted EPS of -$0.10 versus the -$0.13 estimate, a beat of 23.1%. Revenue was $71.6M against a $66.1M estimate. The stock's 1-day post-earnings move was +7.2%.
How much does ADPT stock move after earnings?
ADPT beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.0% (up or down) in the day after earnings.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Q2 2026 | -0.13 | -0.10 | +23.08% | $71.6M | ✅ Beat | +7.18% | +9.04% | +17.20% |
| 2026-07-28 | -0.13 | -0.25 | — | $71.6M | ❌ Miss | +0.09% | +2.53% | +16.46% | |
| 2026-05-05 | Q1 2026 | -0.16 | -0.13 | +18.75% | $70.9M | ✅ Beat | +4.72% | -1.09% | +31.20% |
| 2026-02-05 | Q4 2025 | -0.19 | -0.09 | +52.63% | $71.7M | ✅ Beat | -4.25% | -5.65% | -9.23% |
| 2025-11-05 | Q3 2025 | -0.15 | -0.15 | +0.00% | $60.2M | ➖ Inline | -11.54% | -17.57% | -16.15% |
| 2025-08-05 | Q2 2025 | -0.24 | -0.17 | +29.17% | $58.9M | ✅ Beat | +5.79% | +14.57% | +17.83% |
| 2025-02-11 | Q4 2024 | -0.24 | -0.23 | +4.17% | $47.5M | ✅ Beat | -3.21% | +7.31% | -8.08% |
| 2024-11-07 | Q3 2024 | -0.29 | -0.22 | +24.14% | $46.4M | ✅ Beat | +3.37% | -0.89% | +14.39% |
Showing last 8 quarters.